There are currently 11 studies involving Sipuleucel-T that are getting underway. 8 of those are actively recruiting, the other 3 should be starting soon. 4 of these studies are not sponsored by DNDN. 1 of the studies that is recruiting is related to Europe Manufacturing QA/QC. In addition to the 11 above there are 8 more that are active that are not recruiting patients. That is 19 studies in total.
I think if the drug was a dud, there wouldn't be so much interest in looking it how it works, why it works, if it works better with other cancer meds or by itself, if it is also safe in EU and so forth and so on.
The treatment works and they are trying to figure out why and how to make it work better.
My main point here is that the research community is working on expanding the label and trying to make Provenge work better. Trials take time. So if DNDN can keep its head above water financially, more sales due to label expansion will come. David Miller tweeted from AUA that many physicians are seeing patients that want Provenge but are frustrated that they have to get sicker before the drug is available to them. Currently, Provenge can be prescribed earlier, but insurance will not cover it until a patient has mets. The fact that patients want Provenge is a good thing. It's unfortunate that it is being withheld until people are towards the end of their disease.